+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Anti-Ischemic Agents - Global Market Trajectory & Analytics

  • ID: 5302221
  • Report
  • April 2021
  • Region: Global
  • Global Industry Analysts, Inc

FEATURED COMPANIES

  • Actelion
  • AstraZeneca
  • Baxter, Inc.
  • Bayer AG
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • MORE
Global Anti-Ischemic Agents Market to Reach $384 Million by 2027

Amid the COVID-19 crisis, the global market for Anti-Ischemic Agents estimated at US$263.6 Million in the year 2020, is projected to reach a revised size of US$384 Million by 2027, growing at a CAGR of 5.5% over the period 2020-2027.



The U.S. Market is Estimated at $71 Million, While China is Forecast to Grow at 9% CAGR

The Anti-Ischemic Agents market in the U.S. is estimated at US$71 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$83.4 Million by the year 2027 trailing a CAGR of 9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3% and 4.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.

Select Competitors (Total 45 Featured):
  • AstraZeneca
  • Actelion
  • Bayer AG
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Baxter, Inc.
  • Eli Lilly and Company
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Actelion
  • AstraZeneca
  • Baxter, Inc.
  • Bayer AG
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • MORE
I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Current & Future Analysis for Anti-Ischemic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 2: World Historic Review for Anti-Ischemic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 3: World 15-Year Perspective for Anti-Ischemic Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027
III. MARKET ANALYSIS
  • UNITED STATES
  • Table 4: USA Current & Future Analysis for Anti-Ischemic Agents by Segment - Anti-Ischemic Agents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 5: USA Historic Review for Anti-Ischemic Agents by Segment - Anti-Ischemic Agents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • CANADA
  • Table 6: Canada Current & Future Analysis for Anti-Ischemic Agents by Segment - Anti-Ischemic Agents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 7: Canada Historic Review for Anti-Ischemic Agents by Segment - Anti-Ischemic Agents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • JAPAN
  • Table 8: Japan Current & Future Analysis for Anti-Ischemic Agents by Segment - Anti-Ischemic Agents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 9: Japan Historic Review for Anti-Ischemic Agents by Segment - Anti-Ischemic Agents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • CHINA
  • Table 10: China Current & Future Analysis for Anti-Ischemic Agents by Segment - Anti-Ischemic Agents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 11: China Historic Review for Anti-Ischemic Agents by Segment - Anti-Ischemic Agents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • EUROPE
  • Table 12: Europe Current & Future Analysis for Anti-Ischemic Agents by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 13: Europe Historic Review for Anti-Ischemic Agents by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 14: Europe 15-Year Perspective for Anti-Ischemic Agents by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
  • FRANCE
  • Table 15: France Current & Future Analysis for Anti-Ischemic Agents by Segment - Anti-Ischemic Agents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 16: France Historic Review for Anti-Ischemic Agents by Segment - Anti-Ischemic Agents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • GERMANY
  • Table 17: Germany Current & Future Analysis for Anti-Ischemic Agents by Segment - Anti-Ischemic Agents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 18: Germany Historic Review for Anti-Ischemic Agents by Segment - Anti-Ischemic Agents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • ITALY
  • Table 19: Italy Current & Future Analysis for Anti-Ischemic Agents by Segment - Anti-Ischemic Agents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 20: Italy Historic Review for Anti-Ischemic Agents by Segment - Anti-Ischemic Agents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • UNITED KINGDOM
  • Table 21: UK Current & Future Analysis for Anti-Ischemic Agents by Segment - Anti-Ischemic Agents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 22: UK Historic Review for Anti-Ischemic Agents by Segment - Anti-Ischemic Agents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • SPAIN
  • Table 23: Spain Current & Future Analysis for Anti-Ischemic Agents by Segment - Anti-Ischemic Agents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 24: Spain Historic Review for Anti-Ischemic Agents by Segment - Anti-Ischemic Agents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • RUSSIA
  • Table 25: Russia Current & Future Analysis for Anti-Ischemic Agents by Segment - Anti-Ischemic Agents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 26: Russia Historic Review for Anti-Ischemic Agents by Segment - Anti-Ischemic Agents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • REST OF EUROPE
  • Table 27: Rest of Europe Current & Future Analysis for Anti-Ischemic Agents by Segment - Anti-Ischemic Agents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 28: Rest of Europe Historic Review for Anti-Ischemic Agents by Segment - Anti-Ischemic Agents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • ASIA-PACIFIC
  • Table 29: Asia-Pacific Current & Future Analysis for Anti-Ischemic Agents by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 30: Asia-Pacific Historic Review for Anti-Ischemic Agents by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 31: Asia-Pacific 15-Year Perspective for Anti-Ischemic Agents by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
  • AUSTRALIA
  • Table 32: Australia Current & Future Analysis for Anti-Ischemic Agents by Segment - Anti-Ischemic Agents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 33: Australia Historic Review for Anti-Ischemic Agents by Segment - Anti-Ischemic Agents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • INDIA
  • Table 34: India Current & Future Analysis for Anti-Ischemic Agents by Segment - Anti-Ischemic Agents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 35: India Historic Review for Anti-Ischemic Agents by Segment - Anti-Ischemic Agents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • SOUTH KOREA
  • Table 36: South Korea Current & Future Analysis for Anti-Ischemic Agents by Segment - Anti-Ischemic Agents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 37: South Korea Historic Review for Anti-Ischemic Agents by Segment - Anti-Ischemic Agents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • REST OF ASIA-PACIFIC
  • Table 38: Rest of Asia-Pacific Current & Future Analysis for Anti-Ischemic Agents by Segment - Anti-Ischemic Agents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 39: Rest of Asia-Pacific Historic Review for Anti-Ischemic Agents by Segment - Anti-Ischemic Agents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • LATIN AMERICA
  • Table 40: Latin America Current & Future Analysis for Anti-Ischemic Agents by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 41: Latin America Historic Review for Anti-Ischemic Agents by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 42: Latin America 15-Year Perspective for Anti-Ischemic Agents by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027
  • ARGENTINA
  • Table 43: Argentina Current & Future Analysis for Anti-Ischemic Agents by Segment - Anti-Ischemic Agents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 44: Argentina Historic Review for Anti-Ischemic Agents by Segment - Anti-Ischemic Agents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • BRAZIL
  • Table 45: Brazil Current & Future Analysis for Anti-Ischemic Agents by Segment - Anti-Ischemic Agents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 46: Brazil Historic Review for Anti-Ischemic Agents by Segment - Anti-Ischemic Agents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • MEXICO
  • Table 47: Mexico Current & Future Analysis for Anti-Ischemic Agents by Segment - Anti-Ischemic Agents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 48: Mexico Historic Review for Anti-Ischemic Agents by Segment - Anti-Ischemic Agents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • REST OF LATIN AMERICA
  • Table 49: Rest of Latin America Current & Future Analysis for Anti-Ischemic Agents by Segment - Anti-Ischemic Agents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 50: Rest of Latin America Historic Review for Anti-Ischemic Agents by Segment - Anti-Ischemic Agents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • MIDDLE EAST
  • Table 51: Middle East Current & Future Analysis for Anti-Ischemic Agents by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 52: Middle East Historic Review for Anti-Ischemic Agents by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 53: Middle East 15-Year Perspective for Anti-Ischemic Agents by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027
  • IRAN
  • Table 54: Iran Current & Future Analysis for Anti-Ischemic Agents by Segment - Anti-Ischemic Agents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 55: Iran Historic Review for Anti-Ischemic Agents by Segment - Anti-Ischemic Agents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • ISRAEL
  • Table 56: Israel Current & Future Analysis for Anti-Ischemic Agents by Segment - Anti-Ischemic Agents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 57: Israel Historic Review for Anti-Ischemic Agents by Segment - Anti-Ischemic Agents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • SAUDI ARABIA
  • Table 58: Saudi Arabia Current & Future Analysis for Anti-Ischemic Agents by Segment - Anti-Ischemic Agents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 59: Saudi Arabia Historic Review for Anti-Ischemic Agents by Segment - Anti-Ischemic Agents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • UNITED ARAB EMIRATES
  • Table 60: UAE Current & Future Analysis for Anti-Ischemic Agents by Segment - Anti-Ischemic Agents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 61: UAE Historic Review for Anti-Ischemic Agents by Segment - Anti-Ischemic Agents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • REST OF MIDDLE EAST
  • Table 62: Rest of Middle East Current & Future Analysis for Anti-Ischemic Agents by Segment - Anti-Ischemic Agents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 63: Rest of Middle East Historic Review for Anti-Ischemic Agents by Segment - Anti-Ischemic Agents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • AFRICA
  • Table 64: Africa Current & Future Analysis for Anti-Ischemic Agents by Segment - Anti-Ischemic Agents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 65: Africa Historic Review for Anti-Ischemic Agents by Segment - Anti-Ischemic Agents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
IV. COMPETITION
  • Total Companies Profiled: 45
Note: Product cover images may vary from those shown
  • AstraZeneca
  • Actelion
  • Bayer AG
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Baxter, Inc.
  • Eli Lilly and Company
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi
Note: Product cover images may vary from those shown
Adroll
adroll